Xceed Molecular, based in Toronto and Wellesley, has been acquired by Anaheim, Calif., based Axela Inc. which plans to provide clinical researchers with a suite of products for enhanced analysis of proteins, pathogens, DNA and RNA.
No financial details of the deal were reported. Xceed, headquartered in Toronto with a facility in Wellesley, developed the Ziplex System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip.
Axela, which will move into Xceed’s Toronto headquarters, offers systems that multiplex protein biomarker testing in clinical research and diagnostics.
In 2008, Xceed reported that it had gained an exclusive worldwide license to a gene signature for colon cancer from the Moffitt Cancer Center.